Synergistic bacterial compositions and methods of production and use thereof
Provided are therapeutic compositions containing microbial populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
1. A composition comprising a therapeutically effective amount of a population of bacterial spores, the population of bacterial spores comprising at least one isolated Clostridium disporicum spore comprising a 16S nucleic acid comprising a sequence at least 97% identical to SEQ ID NO:579, at least one isolated Blautia producta spore comprising a 16S nucleic acid comprising a sequence at least 97% identical to SEQ ID NO:379, and at least one isolated Coprococcus comes spore comprising a 16S nucleic acid comprising a sequence at least 97% identical to SEQ ID NO:674, wherein the population of bacterial spores can synergistically decrease and/or inhibit the growth and/or colonization of at least one species of pathogenic bacteria in a human gastrointestinal tract.
2. The composition of claim 1 , wherein the Clostridium disporicum spore comprises a 16S nucleic acid sequence comprising SEQ ID NO:579, and the Blautia producta spore comprises a 16S nucleic acid sequence comprising SEQ ID NO:379, and the isolated Coprococcus comes spore comprises a 16S nucleic acid sequence comprising SEQ ID NO:674.
3. The composition of claim 1 , wherein the population of bacterial spores can synergistically inhibit Clostridium difficile growth in a CivSim assay with a confidence interval of >99%.
4. The composition of claim 1 , wherein the pathogenic bacterium is a Clostridium.
5. A single dose unit comprising the composition of claim 1 .
6. A pharmaceutical formulation comprising an effective amount of the composition of claim 1 , and an effective amount of an anti-bacterial agent, an anti-fungal agent, an anti-viral agent or an anti-parasitic agent.
7. A method of functionally populating the gastrointestinal tract of a human subject, the method comprising administering to the subject an effective amount of the composition of claim 1 .
8. A method for preventing, treating, reducing the severity of or reducing one or more symptoms of a dysbiosis of the gastrointestinal tract in a human subject, the method comprising administering to the subject an effective amount of the composition of claim 1 .
9. A method of reducing the abundance of C. difficile in the gastrointestinal tract of a human subject, the method comprising administering to the subject an effective amount of the composition of claim 1 .
10. A formulation comprising the composition of claim 1 and pharmaceutically acceptable excipient.
11. The composition of claim 1 , wherein the composition is derived from fecal material subjected to ethanol treatment.
12. The composition of claim 1 , comprising a delayed release capsule.
13. The composition of claim 1 , formulated for oral administration.
14. The composition of claim 1 , comprising at least 1×10 4 colony forming units of the purified population of bacterial spores per dose of the composition.